Share

Meet the new EORTC Board

The year 2024 signals the beginning of a new governing mandate. We are delighted to announce that during the General Assembly held on Friday, 28 June 2024, the new EORTC Board was appointed.

We warmly welcome four distinguished new members to our Board: Mrs Caroline Artis, the new Chair of the Audit & Finance Committee; Dr Roberto Salgado, who joins as a board member; Professor Martin van den Bent, the new Chair of the Protocol Review Committee; and Early Career Investigator, Dr Jens Lehmann.

Additionally, we are pleased to announce that Dr Etienne Brain and Dr Mieke Van Hemelrijck have been re-elected for a second term, and Dr Jean-Pierre Bizzari will now serve as Special Advisor. The rest of the board members have been renewed in their current roles.

The full new Board will convene for the first time in September. The current President, Professor W. van der Graaf, will remain in position until June 2026, as approved by the General Assembly, ensuring continuity during the recent changes in the EORTC’s governance structure.

Back to news list

Related News

  • Treatment optimisation: making cancer treatment accessible and sustainable in Europe

  • EORTC celebrates World Radiotherapy Awareness Day (WRAD) through innovation and collaboration in clinical cancer trials

  • 2148 MRD Study reaches milestone with First Patient In (FPI)

  • PET imaging widely used in European brain tumour centres, survey shows

  • New EORTC Leadership: President-Elect and Scientific Chairs Council

  • First Site Activated in EU-Funded DE-ESCALATE Clinical Trial on Advanced Metastatic Prostate Cancer

  • EORTC publishes its 2024 Annual Report: Driving progress in cancer treatment, together

  • EORTC in the spotlight at ASCO 2025

  • EORTC’s presence at ASCO 2025

  • Celebrating Clinical Trials Day 2025 with EORTC’s Young and Early Career Investigators